
The study focuses on improving adjuvant treatment decisions for endometrial cancer by considering molecular subtypes. POLE mutated cases consistently showed positive outcomes. Similarities between p53 abnormality endometrial cancer and high-grade serous ovarian cancer suggested overlapping treatments. Immune checkpoint molecules counteracted immune issues in mismatch repair deficient cases. Hormonal treatment was suggested for high-risk non-specific molecular spectrum cases. Overall, combining clinical and molecular data could enhance treatment selection, involving radiochemo-, chemotherapy, inhibitors, endocrine therapy, and immunotherapy.
Like
Save
Share